Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YB-1113 in Premature Ovarian Insufficiency
NCT05494723Phase 1Not yet recruiting
- Sponsor
- Bright Cell, Inc.
- Start
- Dec 2026
- Primary completion
- Jan 2028
- Modality
- Mesenchymal Stem Cells
01
Overview
Phase 1, open-label trial of YB-1113 in premature ovarian insufficiency (POI) (2 arms), sponsored by Bright Cell, Inc. Primary endpoint: Adverse Events at 52 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
YB-1113
03
Conditions
premature ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT05494723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494723.